TP 271

Drug Profile

TP 271

Alternative Names: TP271

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tetraphase Pharmaceuticals
  • Class Antibacterials; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Community-acquired pneumonia

Most Recent Events

  • 07 Mar 2018 Tetraphase Pharmaceuticals and National Institute of Allergy and Infectious Diseases plans a phase I trial for Bacterial infections (In volunteers) in USA in March 2018 (NCT03450187)
  • 17 Aug 2017 Tetraphase initiates enrolment in a phase I trial in Community-acquired pneumonia (In volunteers) in USA (PO) (NCT03234738)
  • 05 Jun 2017 Phase-I clinical trials in Community-acquired pneumonia (In volunteers) in USA (PO) (NCT03024034)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top